Wragge advises international takeover
Wragge & Co's Birmingham office has advised new client, NYSE-listed Cambrex Corporation, on acquiring a 51 per cent stake in Indian pharmaceutical company Zenara. The purchase was made for $20m.
US-based Cambrex, a life sciences company, will acquire the remaining stake in early 2016 “at a value to be determined”, said Wragge.
The acquisition positions the company as one of the leading global manufacturer's of nicotine replacement therapy products. It is Cambrex's first entrance into the Indian pharmaceutical finished dosage form market.
Wragge’s corporate director Richard Goold said: "This cross-border deal was highly complex, involving international tax and IP advice. Our vast experience of mid-market M&As, life sciences expertise and commercially-sound advice ensured we delivered the right result."
The cross-firm team also included corporate lawyers Nigel Collins, Hannah Salmon and Nick Jones, tax partner Kevin Lowe and IP partner Luke Kempton. Head of transaction services Graham Spalding led the due diligence.
